Literature DB >> 31256679

Fenofibrate ameliorates neural, mechanical, chemical, and electrical alterations in the murine model of heart failure.

N Dhyani1, B Saidullah1, M Fahim2, S Omanwar1.   

Abstract

Heart failure (HF) is a leading cause of hospitalization across the world and is known to cause ill-health and heavy economic losses. In the present study, a rat model of isoproterenol (ISO, 85 mg/kg subcutaneously for two subsequent days) induced HF was developed. ISO induces HF by its direct effect, that is, rise in left ventricular end-diastolic pressure (mechanical) and indirectly by altering the baroreflex (neural), electrocardiography (electrical), and development of oxidative stress and hyperlipidemia (chemical). Fenofibrate, a hypolipidemic drug, which ameliorates myocardial energy metabolism was seen to improve the both ISO-induced oxidative stress and lipid profile and consequently improved Baroreflex Sensitivity (BRS), partial ventricular functions, and cardiac hypertrophy. Therefore, our result suggests that fenofibrate treatment protected the heart by alleviating the ISO-induced effects, that is, neural, mechanical, electrical, and chemical alterations.

Entities:  

Keywords:  Isoproterenol; baroreflex sensitivity; cardiac hypertrophy; fenofibrate; heart failure

Mesh:

Substances:

Year:  2019        PMID: 31256679     DOI: 10.1177/0960327119860173

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  3 in total

1.  Salidroside Ameliorates Cardiomyocyte Hypertrophy by Upregulating Peroxisome Proliferator-Activated Receptor-α.

Authors:  Hui Gao; Kunming Tian; Yichong Meng; Xueping Liu; Yingfu Peng
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

Review 2.  Energy metabolism disorders and potential therapeutic drugs in heart failure.

Authors:  Yanan He; Wei Huang; Chen Zhang; Lumeng Chen; Runchun Xu; Nan Li; Fang Wang; Li Han; Ming Yang; Dingkun Zhang
Journal:  Acta Pharm Sin B       Date:  2020-10-14       Impact factor: 11.413

3.  Bawei Chenxiang Wan Ameliorates Cardiac Hypertrophy by Activating AMPK/PPAR-α Signaling Pathway Improving Energy Metabolism.

Authors:  Xiaoying Zhang; Zhiying Zhang; Pengxiang Wang; Yiwei Han; Lijun Liu; Jie Li; Yichun Chen; Duxia Liu; Jinying Wang; Xiaoying Tian; Qin Zhao; Fengxia Yan
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.